Partial
Partially Aligned
Patient Risk:
Low
Summary
Several claims are broadly consistent with the provided label excerpts (antiplatelet mechanism; IV administration; NSTE-ACS use; hospital IV infusion). However, the response omits key label-specific elements (exact indication population, dosing regimen, contraindications, and bleeding/thrombocytopenia monitoring). Some claims are not supportable from the provided label excerpts (generic availability/marketing under different manufacturers).
Category Scores
Accurate Statements
Tirofiban is an antiplatelet medicine.
Label Mechanism: AGGRASTAT is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor and inhibits ex vivo platelet aggregation (Section 12.1).
Tirofiban is used in certain acute cardiovascular settings to help prevent blood clots.
Indications and Usage: reduce the rate of thrombotic cardiovascular events in patients with NSTE-ACS (Section 1).
Tirofiban is typically given by IV infusion in hospital settings.
Dosage and Administration: recommended dosage is administered intravenously; IV use only (Sections 2.1 and 2.2).
Tirofiban is used for people undergoing procedures or with acute coronary syndromes.
Indications endpoint includes death, myocardial infarction, or refractory ischemia/repeat cardiac procedure in NSTE-ACS (Section 1).
Unsupported Statements
Tirofiban is the generic name itself.
The provided label excerpts do not state that 'tirofiban' is the generic name; excerpts focus on AGGRASTAT and tirofiban hydrochloride as the active ingredient without explicitly mapping generic-name terminology.
Tirofiban is available as a generic medicine.
No information in the provided label excerpts addresses availability as a generic product.
Products with the ingredient tirofiban are marketed under different manufacturers.
No information in the provided label excerpts addresses marketing/manufacturer status for tirofiban products.
Contradictions
Low
AI Statement
Tirofiban is the generic name itself.
Important Omissions
Exact on-label indication wording: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (death, MI, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Importance:
Moderate
Exact recommended dosing regimen (25 mcg/kg IV within 5 minutes then 0.15 mcg/kg/min for up to 18 hours; and renal impairment dose reduction).
Importance:
Moderate
Contraindications (severe hypersensitivity, history of thrombocytopenia following prior exposure, and active internal bleeding/bleeding diathesis/major surgery or severe physical trauma within previous month).
Importance:
Moderate
Key warnings/precautions: risk of bleeding; thrombocytopenia risk; and required platelet monitoring (begin about 6 hours after initiation and daily thereafter; discontinue if confirmed thrombocytopenia and heparin).
Importance:
High
Drug interaction warning: concomitant use of fibrinolytics, anticoagulants, and antiplatelet drugs increases bleeding risk.
Importance:
High
Specific population safety statements included in the provided excerpts (pregnancy, lactation, pediatric, geriatric, renal insufficiency including hemodialysis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not provide detailed dosing or safety management instructions and omits major contraindications, bleeding/thrombocytopenia precautions, and monitoring. These omissions could be clinically important if the response were used for prescribing without consulting the full label, but the provided statements themselves do not directly contradict the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Missing critical label elements (contraindications; bleeding/thrombocytopenia warnings with monitoring; exact dosing and renal adjustment; interaction warning). Also, some claims (generic availability/manufacturer marketing; generic-name statement) are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to label-supported content from provided sections, and add the exact indicated population (NSTE-ACS), on-label dosing regimen (including renal adjustment), contraindications, and key bleeding/thrombocytopenia monitoring and interaction warnings.